Articles tagged with Chemotherapy
Scientists have discovered that thiabendazole, a generic antifungal drug, can decrease blood vessel growth in tumors, starving them of nutrients. The study also found that the drug slows tumor growth, suggesting it could be used in combination with other chemotherapies.
Canada faces unpredictable and widespread drug shortages, affecting patient health and healthcare costs. A national approach with mandatory reporting and integrated leadership can minimize the impact of shortages.
Infants born to mothers who received chemotherapy during pregnancy had lower birth weights but no higher risk of birth defects or blood disorders. The study suggests that breast cancer treatment during pregnancy is possible and prioritizing full-term delivery may be crucial for minimizing risks.
The study found that the absence or downregulation of the LRP1B gene is associated with chemoresistance in high-grade serous ovarian cancer. Additionally, tumors that initially responded to chemotherapy but later became resistant evolved further than those that were resistant from the outset.
Researchers have confirmed that normalizing blood vessels by blocking oxygen sensor PHD2 can make chemotherapy more effective. This strategy also reduces the harmful side effects of chemotherapy on healthy organs.
Researchers have developed a method to find and kill malignant cells while sparing healthy ones using theranostic imaging. The technique relies on binding a potent drug therapy to specific proteins on tumor cell surfaces, allowing it to target cancerous cells with precision.
Cancer cells respond differently to therapy based on their microenvironment, with fibroblasts sustaining DNA damage that promotes growth and resistance. The discovery could lead to more effective treatments by targeting the tumor microenvironment.
A new biomarker, pyridoxal kinase (PDXK), has been identified as a predictor of response to chemotherapy in NSCLC patients. PDXK expression levels are associated with survival rates and treatment outcomes.
Dr. Piyali Dasgupta received a three-year grant to investigate the anti-cancer activity of capsaicin in small cell lung cancer patients. The study aims to improve chemotherapy treatment outcomes, which often relapse quickly and become unresponsive.
A recent study found that patients who received chemotherapy following removal of periampullary cancer experienced improved overall survival compared to those who did not receive chemotherapy. The study also suggested that gemcitabine therapy provided the most significant survival benefit, with a median survival time of 43.1 months.
Researchers at WashU Medicine discovered that ACA11, a non-coding RNA, helps protect cancer cells from damage and makes them resistant to chemotherapy. This finding may lead to new cancer therapeutics and help guide research into better treatments for patients with multiple myeloma.
Researchers have discovered that high levels of protein EYA3 are associated with a poor response to chemotherapy in Ewing's sarcoma patients. Lowering EYA3 levels may help increase the effectiveness of existing therapies and improve outcomes.
Studies using specialized MRI scans show that the procedure can detect whether anti-cancer chemotherapy is working, buying patients many months to a year of life. The scans use software to analyze water movement in tumor cells, identifying those with high and low apparent diffusion coefficients.
A new cancer drug, brentuximab vedotin (Adcetris), has dramatically improved survival rates for Hodgkin lymphoma patients who have failed other treatments. In a multi-center study, 65% of patients were alive at 24 months, and 25% had no progression of the disease.
A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without radiation or intensive chemotherapy, maintaining excellent long-term survival. The study's findings suggest that patients with favorable-risk disease may benefit from minimal treatment approaches.
Researchers have created a dynamic 3D computer model of the human P-glycoprotein, which is thought to contribute to chemotherapy failure in many recurring cancers. The model enables scientists to virtually screen over 8 million potential drug compounds to find one that can help stop chemotherapy resistance.
Researchers found a pediatric treatment regime improves long-term survival and decreases mortality rate by 40% in young adult leukemia patients without bone marrow transplant. The study suggests treating adolescent and adult patients with aggressive chemotherapy like children could lead to better outcomes.
Researchers found that perioperative chemotherapy improved overall survival in patients with limited large cell neuroendocrine tumors or small-cell lung cancer after surgery. The study of 74 patients showed a significant difference in overall survival between those who received chemotherapy and those who did not.
Scientists have found that a long-used anti-cancer drug, cisplatin, can prevent the clumping of an enzyme linked to ALS. This discovery suggests that cisplatin could be a promising lead compound for developing new treatments for the incurable disease.
A Vanderbilt-led study identified a gene expression pattern linked to resistance to breast cancer chemotherapy. The researchers found that tumors with low concentrations of the dual specificity protein phosphatase 4 (DUSP4) were more resistant to chemotherapy, suggesting new therapy options for patients with specific subtypes of breast...
Researchers found that overexpressing 14-3-3 proteins can make tumors resistant to chemotherapy. The study, led by Julián Cerón and Simó Schwartz Jr., reveals a key role for the par-5 gene in DNA damage response and genomic stability.
New nanomedicine cancer treatments aim to focus on tumor cells while sparing healthy tissue, potentially reducing severe side effects. These nanoparticle-based medications can deliver anti-cancer drugs directly to tumors through tiny blood vessel passages.
A clinical trial found that duloxetine reduced painful tingling feelings caused by chemotherapy in 59 percent of patients. The study suggests that this antidepressant may be an effective treatment for chemotherapy-induced peripheral neuropathy pain.
A new study led by University of Rochester Medical Center researcher Barbara L. Asselin shows that giving a cardio-protective drug during cancer treatment may prevent damage to the hearts of childhood leukemia survivors. The study found that the drug Zinecard significantly reduced heart problems and damage in patients who received it.
A new frontline treatment regimen combining carfilzomib, lenalidomide, and low-dose dexamethasone resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. The study found that the regimen was well-tolerated, with improved responses as treatment continued.
A Cleveland Clinic study has detected significant changes in brain activity patterns of patients receiving chemotherapy, supporting the existence of 'chemobrain'. Women showed higher amplitude brain activity after physical and cognitive tasks during treatment.
A new breast cancer treatment, trastuzumab emtansine (T-DM1), has shown significant improvements over standard therapy in keeping advanced tumors from progressing, with fewer and less harsh side effects.
A study by Weizmann Institute scientists reveals that leukemia recurrence is often caused by 'cancer stem cells' that divide slowly, evading chemotherapy drugs. These cells can give rise to new rapidly-dividing cancer cells, making them a key target for new treatment approaches.
A new study shows that Breast MRI provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination. MRI size measurements were superior to clinical examination at all time points, predicting both complete tumor response and residual cancer burden.
A new study suggests that a protein called heat shock factor-1 (HSF-1) is involved in chemotherapy-related heart damage. Researchers propose targeting HSF-1 in the heart as a potential therapy to prevent cardiac damage, potentially leading to improved outcomes for cancer patients undergoing chemotherapy.
A new study has shown that giving a daily low-dose of the chemotherapy drug carboplatin at the same time as radiotherapy significantly prolongs survival in elderly patients with lung cancer. Patients who received combined chemoradiotherapy were nearly a third less likely to die than those given radiotherapy alone.
A new treatment regimen, accelerated MVAC, has been shown to provide comparable benefits to standard chemotherapy without the same toxicity. This accelerated schedule of six weeks has improved response rates and tolerability for patients with muscle-invasive bladder cancer.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
A recent study found that 54% of patients with stage two and three rectal cancer did not receive treatment consistent with guidelines. The study, published in Clinical Oncology, also showed significant regional variation in treatment patterns across Alberta.
Researchers found that administering cyclophosphamide before bone tumors took root fertilized the bone marrow, enabling cancer cells to seed and grow. The study reversed this effect by inhibiting CCL2, suggesting a potential approach for preventing metastasis in certain cancers.
Pazopanib nearly tripled progression-free survival in patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy. The median follow-up was 15 months, and common side effects included fatigue, diarrhoea, and hypertension.
Researchers developed gene expression signatures to predict breast cancer patient responses to chemotherapy. The signatures, based on TOP2A and β-tubulin, accurately predicted complete response rates and combined indices improved accuracy.
Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
Researchers identified a group of patients with high immune response gene expression who are more likely to have their tumors completely eradicated by pre-operative chemotherapy. Patients with HER2-positive and ER-negative/HER2-negative subtypes showed better treatment outcomes.
Researchers at Moffitt Cancer Center found that breast cancer survivors who underwent chemotherapy and/or radiation therapy performed worse on cognitive tests than those who did not have cancer. The study's findings suggest long-term cognitive effects of these therapies need further investigation.
A new analysis of the TORCH trial found that erlotinib is most effective in patients with EGFR mutations, while those with wild-type tumors should receive standard chemotherapy first. The study confirms the importance of biomarker testing to guide treatment decisions.
Researchers analyzed data from 4,168 Medicare beneficiaries with advanced non-small cell lung cancer aged 65 or older. They found no significant difference in overall survival between those treated with bevacizumab and those receiving standard chemotherapy alone. The study's findings suggest that bevacizumab should not be considered th...
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
A study by Dana-Farber Cancer Institute researchers found that adding bevacizumab to standard chemotherapy for non-small cell lung cancer in patients over 65 did not significantly increase survival rates. The treatment approach was previously approved by the FDA but failed to show substantial benefits.
Researchers used live microscopy to observe how cancer cells react to chemotherapy in different tumor microenvironments. Selective inhibition of certain enzymes and immune signaling molecules made breast tumors more responsive to doxorubicin, a widely used chemotherapeutic agent.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Researchers from the University of Hull have identified a family of proteins associated with chemotherapy resistance in breast cancer patients. The 14-3-3 protein family was found to be twice as prevalent in resistant patients, suggesting its potential use as a predictive test for clinical decision-making.
Combining antiangiogenesis drugs with smaller nanomedicines may enhance treatment effectiveness for certain cancers. Vascular normalization temporarily decreases tumor blood vessel diameter, improving drug penetration of smaller particles but not larger molecules.
A new fractionated dosing regimen of gemtuzumab ozogamicin significantly improves event-free survival and overall survival for patients with acute myeloid leukaemia. The regimen reduces toxicity while delivering a high cumulative dose of the drug.
A study found that adding cetuximab to a regimen of drugs after stage III colon cancer surgery did not improve disease-free survival. The trial tested the combination in patients with resected stage III wild-type KRAS colon cancer and showed no benefit.
A genetic marker in blood can determine if a patient with ovarian cancer will benefit from chemotherapy after surgery. This discovery offers hope to patients diagnosed at stage III of the disease, who have a poor prognosis without effective treatment.
A harmless human virus, RT3D, has shown promise in boosting the effects of chemotherapy drugs in advanced head and neck cancer patients. In a Phase I/II trial, approximately one-third of patients experienced tumor shrinkage and disease stabilization.
A Mayo Clinic study found that the dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice. Combining GLA with chemotherapy drug gemcitabine significantly inhibited tumor growth.
Researchers found that activating a cholesterol pathway may enhance chemotherapy's effectiveness against pancreatic cancer. The study used a cholesterol derivative to block the Hedgehog pathway, which is linked to both cancer and heart disease.
A study by Dr. Andreas Engert and colleagues found that six cycles of BEACOPPescalated chemotherapy followed by radiotherapy are more effective in treating advanced Hodgkin's lymphoma with fewer treatment-related events. This approach also reduces toxicity compared to the standard eight-cycle regimen.
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Researchers have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models. The results show that imipramine blue stops tumor invasion and enhances the efficacy of chemotherapy.
Researchers developed a novel compound that stops cancer cells from invading healthy brain tissue, improving treatment outcomes in animal models. The compound, imipramine blue, is combined with chemotherapy to enhance its effectiveness.
Researchers at the University of Alberta discovered that some breast cancer tumors with weak 'survival' systems responded better to taxane chemotherapy than those with strong survival systems. This finding could lead to new strategies for identifying patients who may not respond to this common treatment.